TLC Highlights Data Presentations on Lead Product Candidate TLC599 at Osteoarthritis Research Society International (OARSI) 2019 World Congress

    NEXT STORY
    Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
    PREV STORY
    2019-2023 U.K. Hospital Microbiology Market Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

    author_avatar
    NASDAQ Market News

    Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to…

    Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly ...

    author_avatar
    NASDAQ Market News

    Bavarian Nordic offentliggør positive resultater fra afgørende fase 3 forsøg med koppevaccinen IMVAMUNE®

    Begge primære endemål blev succesfuldt nået Forsøget er det andet positive fase 3 forsøg, ...

    author_avatar
    NASDAQ Market News